证券代码：000790 证券简称：华神科技 公告编号：2024-034 成都华神科技集团股份有限公司 第十三届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届监事会第九 次会议于2024年5月16日以现场表决的方式在公司会议室召开。本次会议通知于 2024年5月13日发出，应到监事3人，实到监事3人，会议由公司监事会主席苏蓉 蓉女士主持，本次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和公司章程的规定。 二、监事会会议审议情况 本议案尚需提交 2023 年年度股东大会审议。 审议通过《关于子公司承接项目工程暨关联交易的议案》 经核查，监事会认为：本次交易属于公司全资子公司四川华神钢构有限责 任公司日常经营活动需要，公司从谨慎性原则按照关联交易审议、披露，决策 程序符合国家有关法律、法规及《公司章程》的规定，依据市场公允价格确定 交易价格，遵循了公开、公平、公正的原则，不存在损害公司和中小股东利益 的情形。具体内容详见公司同日在巨潮资讯网披露的相 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-032 此次交易属于公司全资子公司四川华神钢构有限责任公司（简称"华神钢 构"）日常经营行为，定价政策和定价依据公平、公正、公允，未有损害公司 及其他股东利益的行为。经审议，董事会同意华神钢构承接公司关联方项目工 程事项，授权公司管理层办理相关事宜并签署有关文件。本议案已经 2024 年第 三次独立董事专门会议以及第十三届董事会审计委员会 2024 年第二次会议审议 通过。 关联董事黄明良先生、欧阳萍女士、HUANG YANLING 女士、杨苹女士、王铎 学先生回避表决。 表决结果：同意 4 票，反对 0 票，弃权 0 票，回避 5 票。 本议案尚需提交公司 2023 年年度股东大会审议。 成都华神科技集团股份有限公司 第十三届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第十二次 会议于2024年5月16日以现场与通讯表决相结合的方式在公司会议室召开。本次 会议通知于2024年5月13 ...

1、成都华神科技集团股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日披露了《关于公司间接控股股东增持公司股份计划的公告》（公告编号：2024- 007）。公司间接控股股东成都远泓生物科技有限公司（以下简称"成都远泓"） 计划自 2024 年 2 月 6 日起 6 个月内，通过集中竞价交易或大宗交易方式增持公 司股份，拟增持金额不低于人民币 3,000 万元，不超过人民币 6,000 万元，拟增 持价格不超过人民币 5 元/股 。 2、截至本公告披露日，本次增持计划实施期限已过半，成都远泓通过深圳 证券交易所交易系统以集中竞价交易方式累计增持公司股份 6,280,000 股，占 目前公司总股本的 1%，已支付的总金额约为 1976.36 万元。本次增持计划尚未 实施完毕，成都远泓将继续按照增持计划增持公司股份。2024 年 5 月 6 日，公 司收到成都远泓《关于增持成都华神科技集团股份有限公司股份计划实施进展 的告知函》，现将有关情况公告如下： 证券代码：000790 证券简称：华神科技 公告编号：2024-028 成都华神科技集团股份有限公司 关于公司间接控股股东增持公司股份计划 时间过半的 ...

Financial Performance - The company's operating revenue for 2023 was ¥1,003,376,637.04, representing a 14.92% increase compared to ¥873,103,022.86 in 2022[21]. - The net profit attributable to shareholders decreased by 32.89% to ¥27,659,463.93 from ¥41,217,518.38 in the previous year[21]. - The net cash flow from operating activities dropped significantly by 69.58% to ¥47,414,104.46, down from ¥155,887,751.05 in 2022[21]. - Basic earnings per share fell by 42.86% to ¥0.04, compared to ¥0.07 in the previous year[21]. - Total assets increased by 27.22% to ¥2,133,478,855.05 from ¥1,677,058,446.16 at the end of 2022[21]. - The weighted average return on net assets decreased to 2.72% from 4.15% in 2022, a decline of 1.43%[21]. - The net profit after deducting non-recurring gains and losses was ¥35,421,382.66, a decrease of 7.36% from ¥38,235,775.09 in 2022[21]. - The company's net assets attributable to shareholders increased by 3.00% to ¥1,033,194,655.74 from ¥1,003,077,682.29 at the end of 2022[21]. Dividend Distribution - The company plans to distribute a cash dividend of ¥0.1 per 10 shares, totaling approximately ¥623,719.36 based on 623,719,364 shares[5]. - The company provided cash dividends of 0.10 yuan per 10 shares, totaling 6,237,193.64 yuan, which represents 100% of the profit distribution[150]. - The company plans to distribute dividends based on a total share capital of 623,719,364 shares after deducting restricted shares[151]. - The company has no plans for stock dividends, maintaining a focus on cash distribution to shareholders[151]. Market and Industry Trends - The pharmaceutical industry faced a challenging environment in 2023, with a reported 4% decline in revenue and a 16.2% drop in profit for large-scale pharmaceutical enterprises[30]. - The proportion of loss-making enterprises in the pharmaceutical sector increased to 24.7% in 2023, highlighting the competitive pressures within the industry[30]. - The company plans to expand its market presence in the traditional Chinese medicine sector, which has shown resilience with a revenue growth of 6.5% in 2023[30]. - The health drink business, primarily involving packaged drinking water, is experiencing stable growth, with a projected increase in per capita consumption from 36.95 liters in 2022 to 45.8 liters by 2025 in China[32]. - The steel structure industry is expected to see a processing volume of approximately 107 million tons in 2023, representing a year-on-year growth of about 6.4%[32]. Research and Development - The company is focusing on enhancing its R&D capabilities in response to the government's push for innovation in the pharmaceutical sector, particularly in traditional Chinese medicine[31]. - Research and development expenses rose by 26.71% to ¥31,902,380.11, reflecting increased investment in traditional Chinese medicine and generic drug development[63]. - The company holds 189 patent applications, with 163 granted, including 4 international invention patents, showcasing its strong commitment to innovation and technology development[43]. - The company is focusing on the development of new products, including the clinical application of traditional Chinese medicine and the expansion of its product pipeline[65]. - The company aims to enhance its market competitiveness through the internationalization of its products and the establishment of a strong brand in traditional Chinese medicine[65]. Acquisitions and Investments - The company acquired 70% equity in Shandong Lingkai and 51% equity in Tibet Kangyu, enhancing its market position and production capabilities[48]. - The company completed the acquisition of 70% equity in Shandong Lingkai Pharmaceutical and 51% equity in Tibet Kangyu Pharmaceutical, both of which are now included in the consolidated financial statements[166]. - The company is strategically expanding its market presence through acquisitions, including the recent stake in Xizang Kangyu Pharmaceutical Co., Ltd.[86]. Operational Efficiency - The company has established a comprehensive production quality control system, integrating advanced technologies such as near-infrared online quality monitoring, ensuring the stability of product quality[44]. - The company achieved a 100% pass rate in both internal inspections and external sampling for product quality during the reporting period[50]. - The company is enhancing its project management and incentive mechanisms to improve operational efficiency and adaptability to market changes[95]. - The company is implementing measures to manage raw material costs and mitigate supply risks through strategic procurement and inventory management[98]. Environmental Responsibility - The company strictly adheres to multiple environmental protection laws and standards, ensuring compliance with regulations[172]. - The company has obtained pollution discharge permits and conducts environmental protection management in accordance with legal requirements[173]. - The company reported a total nitrogen discharge of 11.77 mg/L, which is below the regulatory limit of 70 mg/L[174]. - The company has received recognition as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for multiple years, including 2022[183]. - The company invested approximately CNY 1.44 million in environmental protection, focusing on wastewater treatment and air pollution control upgrades[181]. Governance and Management - The company has a complete and independent internal management structure, allowing it to exercise management authority independently[115]. - The company is committed to transparency and regular updates regarding its financial performance and strategic direction[119]. - The company has established a rigorous audit committee to oversee compliance and governance in its financial reporting[140]. - The company is focusing on enhancing its governance structure by ensuring a diverse and experienced board[120]. - The company has actively adopted suggestions from directors to improve its supervisory mechanisms[138]. Future Outlook - The company aims to achieve a net profit growth rate of 80% for 2021 and 30% for 2022, based on 2020 performance[157]. - Future guidance indicates a projected revenue growth of 18% for 2024, aiming for CNY 1.42 billion[132]. - The company plans to continue enhancing its internal control and governance practices based on the audit committee's recommendations[139]. - The company is actively engaging in discussions regarding future growth strategies and operational improvements[141].

Financial Performance - The company's revenue for Q1 2024 was ¥179,277,340.12, a decrease of 18.62% compared to ¥220,289,718.39 in the same period last year[5] - Net profit attributable to shareholders was ¥2,279,754.74, down 28.96% from ¥3,209,240.40 year-on-year[5] - Basic and diluted earnings per share decreased by 29.41% to ¥0.0036 from ¥0.0051 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 179,277,340.12, a decrease of 18.6% compared to CNY 220,289,718.39 in the same period last year[23] - Net profit for Q1 2024 increased to CNY 4,123,269.28, compared to CNY 3,098,819.01 in Q1 2023, representing a growth of 32.9%[24] - Total comprehensive income for the first quarter was CNY 4,123,269.28, an increase from CNY 3,098,819.01 in the previous year[25] - Net income attributable to the parent company was CNY 2,279,754.74, down from CNY 3,209,240.40 year-over-year[25] - Basic and diluted earnings per share were both CNY 0.0036, compared to CNY 0.0051 in the same period last year[25] Cash Flow and Investments - The net cash flow from operating activities improved significantly, reaching -¥25,035,659.98, an increase of 79.13% compared to -¥119,963,874.13 in the previous year[5] - Cash inflow from operating activities totaled CNY 228,953,557.57, up from CNY 140,610,550.26 in the previous year[26] - Net cash flow from operating activities was negative CNY 25,035,659.98, an improvement from negative CNY 119,963,874.13 year-over-year[27] - Cash outflow from investing activities was CNY 37,756,102.86, compared to CNY 46,911,431.72 in the previous year[27] - Net cash flow from financing activities was CNY 49,109,880.09, down from CNY 228,454,523.64 year-over-year[27] - The company's cash and cash equivalents at the end of the period amount to RMB 207,256,110.60, down from RMB 211,179,872.15 at the beginning of the period[20] - The company's cash and cash equivalents were CNY 909,237,950.98, down from CNY 940,337,254.90, a decline of 3.3%[22] - The ending balance of cash and cash equivalents was CNY 103,281,717.07, slightly down from CNY 104,408,862.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,131,733,749.69, a slight decrease of 0.08% from ¥2,133,478,855.05 at the end of the previous year[5] - Total assets as of Q1 2024 were CNY 2,131,733,749.69, a slight decrease from CNY 2,133,478,855.05 in the previous quarter[22] - Total liabilities decreased to CNY 1,051,102,845.71 from CNY 1,057,086,387.08, reflecting a reduction of 0.6%[22] - The company reported a decrease in short-term borrowings to CNY 257,000,000.00 from CNY 276,352,883.33, a reduction of 7%[22] - The total equity attributable to shareholders increased to CNY 1,035,589,577.21 from CNY 1,033,194,655.74, a growth of 0.2%[22] Operational Changes - Operating costs decreased by 38.83% to ¥99,694,789.08, primarily due to changes in sales structure and reduced output in steel structure projects[11] - The company experienced a 67.59% increase in selling expenses to ¥51,295,739.42, attributed to the acquisition of Tibet Kangyu[11] - Cash paid for purchasing goods and services decreased by 31.52% to ¥96,506,277.15, reflecting reduced payments for engineering materials[12] - The company reported a 235.56% increase in cash paid for debt repayment, totaling ¥109,779,500.00, indicating a rise in bank loan repayments[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,590[15] - Sichuan Huashen Group holds 17.74% of shares, with 111,431,281 shares pledged[15] - Chengdu Yuanhong Biotechnology Co., Ltd. plans to increase its stake in the company by investing between RMB 30 million and RMB 60 million, starting from February 6, 2024[17] - Chengdu Yuanhong increased its shareholding by 6,280,000 shares, representing 1% of the total share capital[17] Other Information - The company’s board secretary resigned on March 18, 2024, and the vice president will temporarily assume the role[18] - The company has not undergone an audit for the first quarter report[28] - The company is implementing new accounting standards starting in 2024[28]

成都市高新区交子大道 333 号中海国际中心 E 座 602 室 电话：028-65585333 传真：028-66266533 邮编：610041 北京国枫（成都）律师事务所 关于成都华神科技集团股份有限公司 致：成都华神科技集团股份有限公司（贵公司） 北京国枫（成都）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2024 年第二次临时股东大会（以下简称"本次会议"）。 2024 年第二次临时股东大会的 法律意见书 国枫律股字[2024]D0005 号 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都华神科技 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-014 成都华神科技集团股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席的情况 1、会议召开的时间： （1）现场会议时间：2024 年 4 月 15 日（星期一）下午 14:30 公司总股份 628,142,564 股，通过现场和网络投票的股东 23 人，代表股份 120,392,810 股，占上市公司总股份的 19.1665%。其中：通过现场投票的股东 1 人，代表股份 111,431,281 股，占上市公司总股份的 17.7398%；通过网络投票的 股东 22 人，代表股份 8,961,529 股，占上市公司总股份的 1.4267%。 中小股东出席的总体情况：通过现场和网络投票的中小股东 21 人，代表股 份 2,681,529 股，占上市公司总股份的 0.4269%。其中：通过现场投票的中小股 东 0 人，代表股份 0 股，占上市公司总股份的 0.0000%；通过网络投票的中小股 东 21 人，代表股份 2,681,529 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-013 成都华神科技集团股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相 关的政府补助，是指除与资产相关的政府补助之外的政府补助。上述政府补助 系与收益相关。 2．补助的确认和计量 根据《企业会计准则第16号-政府补助》的相关规定，公司获得的上述政府 补助均属于与收益相关的政府补助，且与公司日常经营活动相关，公司将计入 "其他收益"。 3．补助对上市公司的影响 上述政府补助1,123.12万元列入其他收益，预计对公司2023年度及2024年度 的利润总额产生正面影响，具体的会计处理及其对公司相关财务数据的影响将 以会计师事务所年度审计确认后的结果为准，敬请广大投资者注意投资风险。 三、备查文件 一、获取补助的基本情况 2024 年 3 月 29 日，成都华神科技集团股份有限公司（以下简称"公司"）之 控股子公司西藏康域药业有 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-010 因经营发展需要，为保证全资子公司四川华神钢构有限责任公司（简称 "华神钢构"）、控股子公司山东凌凯药业有限公司（简称"山东凌凯"）的 现金流量充足，华神钢构、山东凌凯拟向银行申请总额为 22000 万元的综合授 信，公司提供不超过 17600 万元的连带责任保证担保。具体内容详见公司在巨潮 资讯网同日披露的相关公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案还需提交股东大会审议。 成都华神科技集团股份有限公司 第十三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第十次 会议于2024年3月29日以现场与通讯表决相结合的方式在公司会议室召开。本次 会议通知于2024年3月26日发出，本次会议应出席董事9人，实际出席董事9人。 会议由公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。本 次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-012 成都华神科技集团股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本次股东大会的召集、召开符合有关法律、行政法规、部门规章、规范性 文件和《公司章程》的规定。 4、会议召开时间： （1）现场会议时间：2024年4月15日（星期一）下午14:30 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第 十次会议审议决定，公司将以现场表决与网络投票相结合的方式召开2024年第 二次临时股东大会。现将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次 成都华神科技集团股份有限公司2024年第二次临时股东大会 2、股东大会的召集人 公司董事会 3、会议召开的合法、合规性 （2）网络投票时间：2024年4月15日 其中：通过深圳证券交易所交易系统进行网络投票的时间为：2024年4月15 日9:15-9:25,9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票 的时间为：2024年4月15 ...